Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $66.94M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.61M
Average 0.60M
ACRV Interest Income
Income earned on cash, deposits, and investments held by the company.
Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income declines year over year
Q1 FY2026 interest income of $989K fell 50.5% year over year, behind the -43.9% change in trailing-twelve-month interest income. Sequentially, it fell 20.7% from the prior quarter.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -50.5% toward the trailing-twelve-month pace of -43.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 6.48M USD
- Year-over-year change
- -29.6%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.48M | -29.6% |
| FY2024 | 2024-12-31 | 9.2M | +30.8% |
| FY2023 | 2023-12-31 | 7.04M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Interest Income vs competitors
How ACRV compares with its peers on the latest reported figures
- ACRV's LTM Mar 2026 interest income of $5.47M is the 2nd highest of the 10 companies compared; the peer median is $1.71M.
- Its year-over-year change of -43.9% is the 7th highest of 9, against a peer median of -36.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.18M | -43.4% | +77.0% | 78.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $5.47M | -43.9% | — | — |
| LTM Mar 2026 | $5.38M | -44.2% | +20.4% | — | |
| LTM Mar 2026 | $1.92M | -34.3% | -19.3% | — | |
| LTM Mar 2026 | $1.84M | -55.1% | +1.0% | — | |
| LTM Mar 2026 | $1.71M | -31.0% | +8.6% | 0.7% | |
| LTM Mar 2026 | $1.62M | -32.2% | -0.0% | — | |
| LTM Mar 2026 | $1.18M | -16.9% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $347K | -37.7% | +94.0% | 8.1% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ACRV) | $1.71M | -36.0% | +8.6% | 4.4% | |
Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 536K | 1.01M | 1.36M |
| Gross Profit | 0 | 0 | (536K) | (1.01M) | (1.36M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.72M | 23.95M | 45.49M | 63.99M | 59.99M |
| Selling, General & Admin | 2.47M | 8.71M | 21.21M | 25.21M | 24.12M |
| Operating Expenses | 16.18M | 32.66M | 66.7M | 88.19M | 82.76M |
| Depreciation & Amortization | 37K | 364K | 536K | 1.01M | 1.36M |
| EBITDA | (16.21M) | (30.8M) | (59.85M) | (79.55M) | (76.55M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (16.18M) | (32.66M) | (67.24M) | (89.2M) | (84.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 7.04M | 9.2M | 6.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (59K) | 1.49M | 6.85M | 8.64M | 6.21M |
| Income Before Tax | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| EPS (Diluted) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| Weighted Avg Shares | 12.91M | 21.92M | 22.08M | 38.3M | 38.51M |
| Weighted Avg Shares (Diluted) | 12.91M | 21.92M | 22.08M | 38.3M | 38.51M |
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
Intrinsic Alpha fair value
Locked
Current Price
$1.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.